Global RNAi Market Analysis

RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents an extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic applications for various indications, and aids in the basic research. Our latest research found that various components, such as siRNA & miRNA possess immense opportunities and provide a wide range in different drug classes. These molecules also find wide applications in sectors, such as functional genomics, disease diagnostics, and agriculture, among others. It is anticipated that the global RNAi market will grow stupendously at a CAGR of around 17% during 2011-2015.

According to our new research report, “Global RNAi Market Analysis”, the incessant growth of the industry will be mainly driven by the rising utilization of the RNAi as a research gizmo in functional genomics, which is used in drug discovery, target validation and drug development along with agricultural & plant biotechnology sectors. RNAi-based therapeutics are one the most lucrative segments, and our report elaborates various applications of RNAi technologies and molecules in the ongoing research and discovery of disease applications, such as oncology, ocular retinal disorders, viral infections and cardiac diseases, among others.

Our report identified that RNAi technologies will have a highly promising outlook as there are several products in the pipeline. Within the sector, therapeutic pipeline products possess a significant potential, which is yet to be tapped. The usage of siRNA and miRNA in industries and academic institutions will witness a substantial growth with the passage of time. Based on exhaustive research, the report identifies some of the key companies present in the RNAi industry, ranging from research-oriented firms to RNAi dedicated products and service providers. We have also enlisted some of the key RNAi products and services having diversely profound applications.

Our report also looks into the key market trends and recent developments across various geographies. The thoroughly examined market applications, industrial developments, and competitive landscape will help clients understand the market structure and its progress in the coming years. Through this comprehensive report, companies planning to venture into the RNAi sector will have an in-depth understanding of the market dynamics.

Global Biological Therapy Industry

1. Analyst View
2. Research Methodology
3. RNAi - An Introduction
4. Industry Overview
4.1 Recent Industry Activities
4.1.1 US
4.1.2 Europe
4.1.3 Asia Pacific
5. RNAi Applications
5.1 Therapeutics
5.2 Drug Discovery & Development
5.3 Agriculture
6. RNAi Technologies by Therapeutic Segment
6.1 Oncology
6.2 Ocular and Retinal Disorders
6.3 Viral Infections
6.4 Cardiac Diseases
6.5 Neuronal and Behavioral Disorders
6.6 Metabolic Syndrome
7. RNAi Technologies by Products and Tools
7.1 RNAi Products
7.1.1 RNAi Inhibitors
7.1.2 RNAi Libraries
7.1.3 RNAi Reagents
7.1.4 RNAi Vectors
7.1.5 RNAi Assays
7.1.6 RNAi Controls
7.1.7 RNAi Mimics
7.2 RNAi Services
8. RNAi Technologies - Pipeline Analysis
9. Recent Industry Trends
9.1 Research Focused on High-Throughput Target Discovery and Target Validation
9.2 Strategic Activity Progressing for Consolidated Developments
9.3 Companies Focusing on Systemic Delivery for RNAi
9.4 Therapeutics: Most Promising Application for RNAi
10. Competitive Landscape
10.1 Alnylam Pharmaceuticals
10.2 Benitec Biopharma Ltd.
10.3 Bioneer Corporation
10.4 Calando Pharmaceuticals
10.5 Dharmacon
10.6 Galena Pharmaceuticals (RXi)
10.7 Integrated DNA Technologies
10.8 Isis Pharmaceuticals
10.9 Life Technologies
10.10 Merck (Sirna)
10.11 Qiagen
10.12 Quark Pharmaceuticals Inc
10.13 Sigma Aldrich Corporation
10.14 Silence Therapeutics
10.15 Tekmira Pharmaceuticals

List of Figures:

Figure 3-1: Process of Viral Replication
Figure 3-2: RNAi Action Mechanism
Figure 3-3: Processing of dsRNA & shRNA
Figure 4-1: Global - RNAi Market (Billion US$), 2011 & 2015

List of Tables:

Table 5-1: Advantages of RNAi Therapies over Conventional Drugs
Table 6-1: Pipeline RNAi Drugs for Oncology
Table 6-2: Pipeline RNAi Drugs for Ocular and Retinal Disorders
Table 6-3: Prevalence Statistics of Viral Infections
Table 6-4: Pipeline RNAi Drugs for Viral Infections
Table 7-1: RNAi Inhibitors Products of Key Companies
Table 7-2: RNAi Library Products of Key Companies
Table 7-3: RNAi Reagent Products of Key Companies
Table 7-4: RNAi Vector Products of Key Companies
Table 7-5: RNAi Assays Products of Key Companies
Table 7-6: RNAi Control Products of Key Companies
Table 7-7: RNAi Mimic Products of Key Companies
Table 7-8: RNAi Services of Key Companies
Table 8-1: Pipeline RNAi Drugs of Key Companies by Phase
Table 10-1: Alnylam - Key RNAi Products in Pipeline
Table 10-2: Benitec - Key RNAi Products in Pipeline
Table 10-3: Bioneer Corporation - Key RNai Products
Table 10-4: Calando Pharmaceuticals - Key RNAi Products in Pipeline
Table 10-5: Dharmacon - Key RNAi Products
Table 10-6: Galena Pharmaceuticals (RXi) - Key RNAi Products in Pipeline
Table 10-7: Integrated DNA Technologies - Key RNAi Products
Table 10-8: Life Technologies Corporation - Key RNAi Products
Table 10-9: Qiagen - Key RNAi Products
Table 10-10: Quark Pharmaceuticals - Key RNAi Products in Pipeline
Table 10-11: Sigma-Aldrich Corporation - Key RNAi Products
Table 10-12: Silence Therapeutics - Key RNAi Products
Table 10-13: Silence Therapeutics - Key RNAi Products in Pipeline
Table 10-14: Tekmira Pharmaceuticals - Key RNAi Products in Pipeline